| Characteristic (N=29∗) | Number (%) |
| Male, n (%) | 21 (72%) |
| Age, median (range) | 64 (54-82) |
| Race/ethnicity | |
| Non-Hispanic White | 21 (72%) |
| Hispanic | 4 (14%) |
| Asian | 3 (10%) |
| Native American | 1 (3%) |
| Creatinine, median (range) | 1.02 (0.56-2.09) |
| Hemoglobin, median (range) | 12 (8-16.1) |
| Albumin, median (range) | 3.8 (1.8-4.7) |
| β2 microglobulin (n = 27), median (range) | 2.9 (1.77-7.5) |
| Calcium | 9.2 (8.5-10.4) |
| Cytogenetics (n = 28) | |
| +1q, n (%)† | 11 (41%) |
| Del(17p), n (%) | 9 (33%) |
| t(4;14) or t(14;16), n (%) | 2 (7%) |
| High risk (+1q, del(17p), t(4;14) or t(14;16)), n (%) | 16 (57%) |
| Double hit | 6 (21%) |
| Previous lines of therapy, median (range) | 2 (1-5) |
| Lenalidomide | 29 (100%) |
| Bortezomib | 25 (86%) |
| Carfilzomib | 8 (28%) |
| Any proteasome inhibitor | 29 (100%) |
| Dexamethasone | 29 (100%) |
| Cyclophosphamide | 8 (28%) |
| Liposomal doxorubicin | 1 (3%) |
| Daratumumab | 2 (7%) |
| Clarithromycin | 2 (7%) |
| Previous autologous stem cell transplant (n = 28), n (%) | 16 (55%) |
| Previous second autologous stem cell transplant | 3 (10%) |
| Characteristic (N=29∗) | Number (%) |
| Male, n (%) | 21 (72%) |
| Age, median (range) | 64 (54-82) |
| Race/ethnicity | |
| Non-Hispanic White | 21 (72%) |
| Hispanic | 4 (14%) |
| Asian | 3 (10%) |
| Native American | 1 (3%) |
| Creatinine, median (range) | 1.02 (0.56-2.09) |
| Hemoglobin, median (range) | 12 (8-16.1) |
| Albumin, median (range) | 3.8 (1.8-4.7) |
| β2 microglobulin (n = 27), median (range) | 2.9 (1.77-7.5) |
| Calcium | 9.2 (8.5-10.4) |
| Cytogenetics (n = 28) | |
| +1q, n (%)† | 11 (41%) |
| Del(17p), n (%) | 9 (33%) |
| t(4;14) or t(14;16), n (%) | 2 (7%) |
| High risk (+1q, del(17p), t(4;14) or t(14;16)), n (%) | 16 (57%) |
| Double hit | 6 (21%) |
| Previous lines of therapy, median (range) | 2 (1-5) |
| Lenalidomide | 29 (100%) |
| Bortezomib | 25 (86%) |
| Carfilzomib | 8 (28%) |
| Any proteasome inhibitor | 29 (100%) |
| Dexamethasone | 29 (100%) |
| Cyclophosphamide | 8 (28%) |
| Liposomal doxorubicin | 1 (3%) |
| Daratumumab | 2 (7%) |
| Clarithromycin | 2 (7%) |
| Previous autologous stem cell transplant (n = 28), n (%) | 16 (55%) |
| Previous second autologous stem cell transplant | 3 (10%) |